Xencor, Inc. XNCR R2KR3KPHARMA

Q: What is the current share price of Xencor, Inc. (XNCR)?

As of 2026-10-23 16:27 PDT, Xencor, Inc. (XNCR) trades at $25.18 on NasdaqGM. Its 52-week range is $7.44 to $29.30.

Q: What is the market capitalisation of XNCR?

Xencor, Inc. (XNCR) has a market capitalisation of $1.87B on NasdaqGM.

Q: What is the P/E ratio of XNCR?

XNCR trades at a trailing price-to-earnings (P/E) ratio of -11.66. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.65.

Q: What is the return on equity (ROE) of XNCR?

XNCR has a return on equity (ROE) of -29.07%. Its return on capital employed (ROCE) is -22.77%.

Q: Is XNCR a good stock to buy?

This page provides a data-driven analysis of Xencor, Inc. (XNCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.xencor.com

Company Profile ↓

$25.18

+226.17% 1Y

Mkt Cap$1.87B

P/E-11.66

P/B3.65

52W High$29.30

52W Low$7.44

Book Value$6.77

EPS (TTM)$-2.16

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.34.

Recent Developments

Dec 2025 Revenue of $125.58M (+13.7% YoY); net profit $-91.92M.
Trailing 12 Months Year-on-year growth — revenue +17.5%.
5-Year Trend Long-term compounding — revenue CAGR 1.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	1.58%
1 Year:	17.50%

Stock Price Performance

1 Year:	+226.17%
6 Months:	+93.99%
3 Months:	+26.79%
1 Month:	+5.44%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 81% of range

$7.44 $29.30

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)53.87 · Neutral

Price Performance

1M+5.44%

3M+26.79%

6M+93.99%

1Y+226.17%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-11.66

Industry PE

25.45

Forward P/E

-7.10

PEG Ratio

Book Value

$6.77

Price to Book

3.65

P/S

17.51

EV/EBITDA

-7.54

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

1.58%

Profit 5Y

Revenue (YoY)

17.50%

Earnings (YoY)

Profitability & Returns

ROCE

-22.77%

ROE

-29.07%

ROA

-16.84%

Profit Margin

Op Margin

-72.37%

Gross Margin

EPS (Latest Qtr)

$-0.29

EPS (TTM)

$-2.16

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

6.09

Current Ratio

6.39

Debt

$170.11M

Total Assets

$724.96M

Current Assets

$482.86M

Working Capital

$503.91M

Ownership

Promoter Holding

1.22%

Chg in Prom Hold

-0.00%

FII / Inst Holding

114.50%

Chg in FII Hold

-0.04%

Financial Snapshot

Enterprise Value

$1.87B

Total Revenue (TTM)

$104.97M

EBITDA

$-205.90M

Free Cash Flow

$-94.54M

Operating Cash Flow

$-205.81M

Shares Outstanding

74.35M

Gross Margin

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	XNCR Xencor, Inc. R2KR3KPHARMA	25.18	-11.66	$1.87B	0.00%	-22.77%	-29.07%	1.58%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,273.46	42.83	$1.14T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	263.81	30.60	$635.76B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	285.64	80.69	$504.76B	2.54%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	418.09	26.85	$375.28B	2.47%	9.74%	14.15%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPXR3KPHARMA	145.27	116.22	$358.41B	2.31%	-	6.96%	5.64%	10.01%
7	NVS Novartis AG PHARMA	151.12	22.83	$287.24B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	171.49	25.63	$265.96B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	673.82	36.30	$249.14B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	3.50M	12.50M	-	30.15M	-	-	29.04M	11.56M	111.94M	19.48M	21.76M	3.52M	32.38M	13.09M	35.37M	41.85M	33.97M	67.45M	19.68M	85.50M	30.18M	27.30M	18.96M	45.52M	59.16M	16.00M	23.91M	17.80M	32.73M	43.61M	21.00M	28.24M	4.52M	51.22M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75.92M	76.78M	68.52M	81.86M	82.38M	-
Operating Income	-10.31M	7.44M	-6.73M	48.56M	-9.26M	-10.03M	-16.36M	-8.51M	-23.58M	5.33M	-30.65M	-28.29M	651.00K	-21.08M	78.24M	-19.57M	-14.28M	-30.57M	-8.78M	-37.60M	-16.72M	-13.70M	-15.67M	9.09M	-41.30M	26.47M	-28.00M	-38.35M	-60.74M	-26.00M	-18.27M	-54.66M	-55.37M	-55.20M	-43.18M	-33.17M	-47.52M	-53.63M	-77.86M	-37.07M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-36.91M	-20.18M	4.23M	5.67M	-121.37M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.66M	8.24M	7.67M	7.35M	4.70M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-48.27M	-31.07M	-6.03M	-4.27M	-128.64M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	367.00K	-250.00K	0	2.39M	280.00K	-
Net Income	-10.04M	7.76M	-6.40M	47.16M	-8.08M	-9.06M	-15.47M	-7.72M	-22.65M	7.37M	-29.49M	-25.87M	3.15M	-18.20M	80.05M	-16.03M	-10.22M	-26.91M	-8.07M	-35.02M	-12.55M	-13.69M	-2.49M	52.25M	-40.19M	23.59M	-33.98M	-32.76M	-60.76M	-21.95M	-24.27M	-73.44M	-67.34M	-46.29M	-48.42M	-30.82M	-6.03M	-6.65M	-128.92M	-21.73M
Diluted EPS	-0.25	0.19	-0.16	1.13	-0.20	-0.21	-0.33	-0.17	-0.48	0.15	-0.62	-0.46	0.05	-0.32	1.38	-0.28	-0.18	-0.47	-0.14	-0.61	-0.22	-0.24	-0.04	0.87	-0.69	0.39	-0.57	-0.55	-1.02	-0.37	-0.40	-1.20	-1.09	-0.72	-0.66	-0.41	-0.08	-0.09	-1.71	-0.29
R&D Expense	10.58M	-	10.04M	14.41M	14.07M	-	15.05M	16.92M	19.41M	-	26.09M	23.33M	20.95M	-	28.18M	33.30M	29.77M	-	33.94M	43.46M	44.45M	-	41.41M	49.50M	50.61M	47.76M	47.08M	53.27M	65.55M	60.06M	64.94M	56.87M	61.53M	58.23M	58.58M	61.66M	54.37M	-	64.67M	71.91M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	109.02M	46.15M	40.60M	156.70M	122.69M	275.11M	164.58M	174.62M	110.49M	125.58M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	247.05M	306.98M	288.90M	303.08M
Operating Income	-6.23M	-10.52M	-16.46M	-18.34M	44.04M	-43.12M	-79.37M	13.82M	-76.80M	43.77M	-82.47M	-132.36M	-178.41M	-177.50M
EBITDA	-	-	-	-	-	-	-	-	-	-	-45.70M	-101.96M	-186.17M	-47.19M
Interest Expense	-	-	-	-	-	-	-	-	-	-	13.00K	6.18M	36.64M	31.93M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-54.51M	-119.63M	-234.92M	-89.63M
Tax Provision	-	-	-	-	-	-	-	-	-	-	673.00K	13.66M	1.62M	2.50M
Net Income	-8.59M	-60.26M	-16.42M	-17.59M	45.12M	-38.49M	-70.41M	26.88M	-69.33M	82.63M	-55.18M	-133.13M	-232.62M	-91.92M
Diluted EPS	-118.86	-3.85	-0.52	-0.45	1.07	-0.82	-1.31	0.46	-1.21	1.37	-0.93	-2.08	-3.58	-1.24
R&D Expense	12.67M	17.00M	18.52M	34.14M	51.87M	71.77M	97.50M	118.59M	169.80M	192.51M	199.56M	253.60M	227.69M	239.43M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	87.31M	67.82M	206.91M	428.56M	390.20M	576.73M	670.25M	703.24M	-	846.27M	965.13M	951.95M	875.50M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	675.34M	635.60M	577.60M	599.82M
Cash & Equivalents	14.54M	2.31M	77.97M	54.65M	12.59M	14.53M	16.53M	26.25M	50.31M	163.54M	-	53.94M	53.79M	40.88M	54.07M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	29.00M	23.74M	60.85M	29.30M
Total Liabilities	-	-	13.78M	8.53M	44.48M	114.61M	73.74M	55.05M	77.05M	130.80M	-	118.77M	303.05M	277.92M	239.91M
Current Liabilities	-	-	7.48M	6.20M	43.43M	106.29M	72.65M	53.85M	66.56M	121.06M	-	63.84M	73.92M	87.43M	95.91M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	161.77M	115.16M	76.48M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	59.63M	251.94M	231.95M	187.75M
Total Equity	-157.70M	-166.27M	73.53M	59.29M	162.43M	337.93M	316.46M	521.68M	593.20M	572.44M	-	727.50M	661.75M	677.61M	635.59M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	60.00M	61.00M	70.26M	71.87M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	26.67M	95.24M	-33.60M	-79.76M	64.37M	-5.00M	-	24.48M	-77.93M	-202.19M	-135.12M
Investing Cash Flow	-	-	-	-185.11M	-214.27M	31.86M	-164.77M	-50.97M	100.19M	-	-119.72M	-111.06M	-7.87M	139.99M
Financing Cash Flow	-	-	-	116.38M	120.97M	3.73M	254.24M	10.66M	18.04M	-	5.70M	189.22M	197.15M	8.23M
Capital Expenditure	-41.00K	-136.00K	-780.00K	-1.93M	-1.51M	-5.31M	-7.21M	-7.35M	-10.54M	-	-43.40M	-21.25M	-9.51M	-3.15M
Free Cash Flow	-	-	-	24.74M	93.73M	-38.91M	-86.97M	57.02M	-15.54M	-	-18.92M	-99.18M	-211.70M	-138.27M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-89.54M	228.00K	-12.91M	13.10M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	40.4%	-93.4%	-195.5%	8.8%	-62.6%	15.9%	-50.1%	-75.8%	-161.5%	-141.4%
Net Margin %	-	-	-	-	41.4%	-83.4%	-173.4%	17.2%	-56.5%	30.0%	-33.5%	-76.2%	-210.5%	-73.2%
ROE %	5.2%	-81.9%	-27.7%	-10.8%	13.4%	-12.2%	-13.5%	4.5%	-12.1%	-	-7.6%	-20.1%	-34.3%	-14.5%
ROCE %	-	-13.2%	-26.7%	-11.2%	13.7%	-13.6%	-15.2%	2.3%	-13.2%	-	-10.5%	-14.9%	-20.6%	-22.8%

Shareholding Pattern

Insiders

1.22%

Institutions

114.50%

Public Float

115.91%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	18.36%	13.65M	$336.23M
2	Primecap Management Company	13.69%	10.18M	$250.77M
3	BVF Inc.	9.59%	7.13M	$175.70M
4	RTW Investments LP	9.12%	6.78M	$166.93M
5	RA Capital Management, L.P.	7.09%	5.27M	$129.91M
6	State Street Corporation	6.66%	4.95M	$122.02M
7	Vanguard Capital Management LLC	4.41%	3.28M	$80.76M
8	TCG Crossover Management, LLC	3.30%	2.45M	$60.40M
9	Price (T.Rowe) Associates Inc	3.17%	2.36M	$58.04M
10	Vanguard Portfolio Management LLC	2.98%	2.22M	$54.57M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XNCR

Google News Wed, 21 Oct 2026

Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFB2Ykp4Q0ZjZ0plUFVnTkNaRm9RdTdoSEZvZVloSHZZMGUxSUlMdW9vNXc1QVNGSkQ5bWRsTmEwdktUVG1FVGl2YmJFRFNMaGU5Znc?oc=5" target="_blank">Xencor, Inc. (XNCR) Stock Price, News, Quote & History</…

Google News Fri, 23 Oct 2026

Xencor (NASDAQ:XNCR) Earns "Outperform" Rating from Wedbush - MarketBeat

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNOU5oVm5FeGZ5bjVFbi1TNlFTYk1ZNVFyN2tZZzV4ZXBBX2IwekxVYk4tdEk3cDY1dGd2S3BEUDQ4Mzh5WVpoNDlXVVA5ZllrZGhvZmN2ZTJrQ2FTZGNwQ0l0R3N4Y2JwZGJiX3VYTWVOMGJwQ0xjMkNSemdnVVpseDNOYTVqR2tGb0QxUF…

Google News hu, 22 Oct 2026

Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQa1F6WHJ0UlFIcWcwUy1qdTRjakE0WVlCUFhPbU5qeFVZMkppVjY1OTdoZ1g4Zk5oeDlaZ3hqYmRjMXkxdWdYTmdCSnlxZ1F5cFhvbzBpWkxETktsM1RqSXZyREMzQnFhVjZ5RUpRX2k3UFFPT292N19GdjhKcEZpUmR4dWZ6OGJDZjZnQV…

Google News Mon, 19 Oct 2026

A kidney cancer study’s results will be presented in Madrid Oct. 25 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQZFN2eXNfdkMxSnJtV1EybG9aMzF1SllKUnFlLWczd2dDNTF5REptTEYzWHNWOFNLQUJvN0xJR1dSakdPTGdzWmpYQUNUQWl4UUd6THlNOGwydHpBWXhoaGhJalZ6SVBsRDN5MXd0TGFjYWtNYk90OFRDTFJjbEMxQXY0cHpMYTJDTHVHX2…

Google News hu, 25 Jun 2026

XNCR Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBRcldHemJoTnMwY1lZeHlaMEdiVUFnZ2o2bVdIQXk1WDJyN3pGNV9oYl9IYXZ5YVhYN1ZaY1ZieENtUDBvTXpuUTd1cTY3LUNmNDlIMVFPb2NFYm9abHdpT2JOZm44QzItbzNwSGpGbE9OdmdSYWppSjZn?oc=5" target="_blank">XNC…

Google News Wed, 07 Oct 2026

Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOZ3BteXNKUURLTk82M0FFQUEtN0FiTUt5cXJNNDFmRVNXVWJvd0NEWjI2SWd1ZERWaXZPWHZVb2hrYm1BZ205a3hRb0VmemlESlVtUkVTMWFMVjZhcW9sSVZSNXNOLW5JUXdQdzVESGtrVWU4c2k3ejh4aGh3emxPYldIbw?oc=5" targe…

XNCR — Frequently Asked Questions

What is the current share price of Xencor, Inc. (XNCR)?

As of 2026-10-23 16:27 PDT, Xencor, Inc. (XNCR) trades at $25.18 on NasdaqGM. Its 52-week range is $7.44 to $29.30.

What is the market capitalisation of XNCR?

Xencor, Inc. (XNCR) has a market capitalisation of $1.87B on NasdaqGM.

What is the P/E ratio of XNCR?

XNCR trades at a trailing price-to-earnings (P/E) ratio of -11.66. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.65.

What is the return on equity (ROE) of XNCR?

XNCR has a return on equity (ROE) of -29.07%. Its return on capital employed (ROCE) is -22.77%.

Is XNCR a good stock to buy?

This page provides a data-driven analysis of Xencor, Inc. (XNCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Xencor, Inc. XNCR R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Xencor (NASDAQ:XNCR) Earns "Outperform" Rating from Wedbush - MarketBeat

Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance

A kidney cancer study’s results will be presented in Madrid Oct. 25 - Stock Titan

XNCR Forecast — Price Target — Prediction for 2027 - TradingView

Xencor Stock: Better Funding For Obexelimab (NASDAQ:XNCR) - Seeking Alpha

XNCR — Frequently Asked Questions

What is the current share price of Xencor, Inc. (XNCR)?

What is the market capitalisation of XNCR?

What is the P/E ratio of XNCR?

What is the return on equity (ROE) of XNCR?

Is XNCR a good stock to buy?

Explore More